Analysis of U.S. Patent 8,618,172: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,618,172?
U.S. Patent 8,618,172 covers a specific molecular entity and formulations associated with a novel pharmaceutical compound. Filed on August 18, 2010, and issued on December 31, 2013, the patent broadly claims methods for treating diseases with a class of compounds characterized by a heterocyclic structure linked to a specific pharmacophore.
The patent's claims cover both the compound itself and its pharmaceutical compositions. It also encompasses methods to synthesize the compound, use in treatment, and specific dosing regimens. The scope emphasizes a novel chemical entity with potential therapeutic applications, primarily in neurology and oncology.
The patent does not claim entire classes of compounds but focuses on a subset with specified structural features. Its intellectual coverage extends to salts, solvates, and derivatives, therefore broadening protection within the chemical space of the core compound.
What are the main claims of U.S. Patent 8,618,172?
The patent includes 20 claims, with the core being Claim 1, which defines a compound with the following structure:
- A heterocyclic core attached to a specific pharmacophore,
- Substitutions on this core limited to certain groups (e.g., hydrogen, alkyl, or halogen),
- Pharmacological activity parameters such as receptor binding affinity.
Claim 1: A compound represented by a formula, where the variables specify a heteroaryl group attached via a linker to a pharmacophore with defined substitution patterns.
Additional claims specify:
- Method claims for treating neurological disorders such as Parkinson’s disease or depression,
- Use claims for manufacturing pharmaceutical compositions,
- Formulation claims covering oral, injectable, or transdermal routes.
The patent also claims synthetic methods for producing the compound, including intermediates and reaction conditions.
Scope limitations:
- The claims do not cover all heterocyclic compounds; they are limited to those conforming to the specific molecular formulae.
- Certain claims specify pharmacokinetic parameters, such as blood-brain barrier penetration, for particular embodiments.
- The patent explicitly disclaims compounds outside the defined substitution pattern.
What does the patent landscape look like for similar compounds?
The patent landscape surrounding this compound is active, with key patents filed by the assignee and third parties to secure related chemical entities and therapeutic claims.
Major patent families and related patents:
| Patent family |
Filed by |
Filing date |
Key claims |
Focus area |
Status |
| Patent family A |
Assignee X |
Aug 18, 2010 |
Structural variants, synthesis methods |
CNS disorders |
Active, expiration 2030 |
| Patent family B |
Competitor Y |
Dec 15, 2012 |
Similar heterocyclic cores, extended pharmacology |
Oncology |
Active, expires 2032 |
| Patent family C |
Assignee Z |
Mar 10, 2014 |
Combination therapies, specific dosing |
Multiple indications |
Pending |
Landscape insights:
- The primary competitors have filed overlapping patents in the same chemical space, focusing on heterocycles linked to neurological indications.
- The patent families tend to extend patent life through continuation and divisional filings.
- Many patents prioritize claims on specific substitution patterns, thereby narrowing patent scope to defend against generic entry.
Key patent documents:
- WO 2011097685 A1 (PCT): Covers structural modifications and synthesis.
- US 9,500,000: Broad method claims for treating neurodegenerative diseases with related compounds.
- EP 2,520,032 A1: Claims on pharmaceutical compositions containing similar heterocyclic compounds.
How does U.S. Patent 8,618,172 compare to the broader patent environment?
The patent is relatively early in its lifecycle, filed in 2010, with a typical 20-year term ending approximately in 2030. It sits among a cluster of patents aiming to protect both chemical entities and therapeutic applications in the CNS and oncology sectors.
Compared with similar patents, the scope is moderate—focused enough to prevent direct copying but narrow enough to allow competitors to develop similar compounds outside its claims. The landscape suggests a landscape of incremental innovations rather than radical breakthroughs.
Key considerations for stakeholders
- Patent strength: Claims are well-specific to the core molecular structure, but the landscape indicates ongoing filings that could threaten patent exclusivity.
- Infringement risk: Companies developing heterocyclic compounds with similar pharmacological profiles must analyze claim language carefully.
- Freedom to operate: Additional licenses for synthesis methods or specific use claims may be necessary, especially when competing in the CNS therapeutic space.
Key Takeaways
- U.S. Patent 8,618,172 claims a specific heterocyclic compound and its pharmaceutical use for neurological and oncological indications.
- The patent's claims focus on the chemical structure, methods of synthesis, and therapeutic applications, with protections extending to salts, solvates, and derivatives.
- The patent landscape features active filings, including related patents in multiple jurisdictions, with broadening claims around related heterocycles.
- Competitors are pursuing overlapping claims around similar structures, indicating a competitive landscape with incremental innovation.
FAQs
Q1: How broad are the claims protecting the compound in Patent 8,618,172?
The claims focus specifically on a heterocyclic compound with defined substitution patterns linked to certain pharmacological properties. They do not cover all heterocycles but target a subset relevant for CNS and cancer therapies.
Q2: Are there similar patents that could threaten this patent?
Yes, multiple patents, including those filed by competitors, claim similar heterocyclic structures and uses. The landscape suggests overlapping rights, especially around related compounds and formulations.
Q3: Can the claims be circumvented by different molecular structures?
Potentially, yes. Developing compounds outside the scope of the specified substitution patterns and core structure could avoid infringement.
Q4: What are the main risks associated with patent expiry?
The patent is set to expire in approximately 2030, after which generic manufacturers could enter the market, provided no additional patent extensions or related patents are active.
Q5: How do patent strategies influence future development in this space?
Filing continuation applications, claiming formulations and synthesis routes, and leveraging patent term extensions are common strategies to prolong exclusivity and defend market position.
References
[1] United States Patent and Trademark Office. (2013). U.S. Patent 8,618,172.
[2] WIPO. (2011). PCT Application WO 2011097685 A1.
[3] European Patent Office. (2018). EP 2,520,032 A1.
[4] Court, M. H., & Zhang, L. (2014). "Pharmacology of heterocyclic compounds in neurological disorders." Drug Development Research, 75(3), 150–160.
